# Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

> **NCT06931704** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 176 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06931704
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2030-11-30
- **Final completion:** 2031-11-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931704, "Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06931704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*